This feature looks at the approach taken by Oxford Technology Management (OTM) to making and managing investments in start-up and early-stage technology-based businesses with high growth prospects. It takes its content from a PharmaTelevision interview in which Fintan Walton, CEO of PharmaVentures, talked to Dr Matthew Frohn, Director of OTM. The topics discussed include: Venture Capital Trusts (which are unique to the UK); OTM#8217;s requirements for investee companies #8211; which include locality, appropriate technology mix and the associated range of product timelines; reasons for failure and success; and the future development of OTM#8217;s investment funds.